Skip to main content
Log in

Effect of survivin regulation of transcription level by p21waf1 overexpression in HepG2 hepatocellular carcinoma cells

  • Published:
Journal of Huazhong University of Science and Technology [Medical Sciences] Aims and scope Submit manuscript

Summary

The effect of cyclin-dependent kinase inhibitors Cip1/Waf1 (p21) on regulatory expression of survivin transcription in human hepatocellular carcinoma cell HepG2 was observed and the related mechanisms explored. Doxorubicin (DOX) was used to treat HepG2. Eukaryotic vector pEGFP-C2-p21 was transfected into HepG2 by lipofectamine and positive clones were screened out by G418. The mRNA expression of p21 and survivin was detected by real-time fluorescent quantitative polymerase chain reaction (RQ-PCR). Flow cytometry was used to examine the cell cycle, and reverse transcription polymerase chain reaction (RT-PCR) was used to measure the levels of E2F-1 and p300. The results showed that: (1) After treatment with DOX, the expression of p21 was increased, whereas that of survivin was reduced during 24 h of treatment; (2) After transfection of pEGFP-C2-p21 into HepG2, p21 level was significantly enhanced to 2100.11-folds or 980.89-folds in comparison to HepG2 or HepG2-C2 group, and survivin level was markedly down-regulated to 0.54% or 0.59% relative to the control groups; (3) Overexpressed p21 resulted in G1/G0 phase arrest (F=31.59, P<0.01), meanwhile E2F-1 mRNA and p300 mRNA were reduced as compared with those of controls (F E2F-1=125.28, P<0.05; F p300=46.01, P<0.01). It was suggested that p21 could be a potential mediator of survivin suppression at transcription level in HepG2 cell, which might be through the block at G1/G0 phase and down-regulation of transcription factors E2F-1 and p300.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Takashima H, Nakajima T, Moriguchi M et al. In vivo expression patterns of survivin and its splicing variants in chronic liver disease and hepatocellular carcinoma. Liver Int, 2005,25(1):77–84

    Article  CAS  PubMed  Google Scholar 

  2. Lekanne Deprez R H, Fijnvandraat A C, Ruijter J M et al. Sensitivity and accuracy of quantitative real-time polymerase chain reaction using SYBR green I depends on cDNA synthesis conditions. Anal Biochem, 2002, 307(1):63–69

    Article  CAS  PubMed  Google Scholar 

  3. Li Y R, Wu J M, Wang L et al. Detection of telomerase activity and the expression of telomerase subunits in the patients with acute myelogenous leukemia. J Huazhong Univ Sci Technol [Med Sci], 2004,24(1):48–52

    CAS  Google Scholar 

  4. Altieri D C. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene, 2003,22(53):8581–8589

    Article  CAS  PubMed  Google Scholar 

  5. Lohr K, Moritz C, Contente A et al. p21/CDKN1A mediates negative regulation of transcription by p53. J Biol Chem, 2003,278(35):32 507–32 516

    Article  Google Scholar 

  6. Zhou M, Gu L, Li F et al. DNA damage induces a novel p53-survivin signaling pathway regulating cell cycle and apoptosis in acute lymphoblastic leukemia cells. J Pharmacol Exp Ther, 2002,303(1):124–131

    Article  CAS  PubMed  Google Scholar 

  7. Ravizza R, Gariboldi M B, Passarelli L et al. Role of the p53/p21 system in the response of human colon carcinoma cells to doxorubicin. BMC Cancer, 2004,4:92

    Article  PubMed  Google Scholar 

  8. Li Y, Xie M, Yang J et al. The expression of antiapoptotic protein survivin is transcriptionally upregulated by DEC1 primarily through multiple spl binding sites in the proximal promoter. Oncogene, 2006,25(23):3296–3306

    Article  CAS  PubMed  Google Scholar 

  9. Nawrocki S T, Carew J S, Douglas L et al. Histone deacetylase inhibitors enhance lexatumumab-induced apoptosis via a p21Cipl-dependent decrease in survivin levels. Cancer Res, 2007,67(14):6987–6994

    Article  CAS  PubMed  Google Scholar 

  10. Jiang Y, Saavedra H I, Holloway M P et al. Aberrant regulation of survivin by the RB/E2F family of proteins. J Biol Chem, 2004,279(39):40 511–40 520

    Article  CAS  Google Scholar 

  11. Chan H M, La Thangue N B. P300/CBP proteins: HATs for transcriptional bridges and scaffolds. J Cell Sci, 2001,114(Pt 13):2363–2373

    CAS  PubMed  Google Scholar 

  12. Mirza A, McGuirk M, Hockenberry T N et al. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene, 2002,21(17):2613–2622

    Article  CAS  PubMed  Google Scholar 

  13. Garcia-Wilson E, Perkins N D, P21WAF1/CIP1 regulates the p300 sumoylation motif CRD1 through a C-terminal domain independently of cyclin/CDK binding. Cell Cycle, 2005,4(8):1113–1119

    CAS  PubMed  Google Scholar 

  14. Ma H, Nguyen C, Lee K S et al. Differential roles for the coactivators CBP and p300 on TCF/-catenin-mediated survivin gene expression. Oncogene, 2005, 24(22):3619–3631

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Additional information

This project was supported by a grant from Specialized Research Fund for the Doctoral Program of Higher Education (No. 20060487045).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Xiong, J., Hu, L., Li, Y. et al. Effect of survivin regulation of transcription level by p21waf1 overexpression in HepG2 hepatocellular carcinoma cells. J. Huazhong Univ. Sci. Technol. [Med. Sci.] 28, 308–313 (2008). https://doi.org/10.1007/s11596-008-0318-z

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11596-008-0318-z

Key words

Navigation